RESUMO
Lung cancer is one of the most common malignant tumors. Despite decades of research, the treatment of lung cancer remains challenging. Non-small cell lung cancer (NSCLC) is the primary type of lung cancer and is a significant focus of research in lung cancer treatment. The deubiquitinase ubiquitin-specific protease 28 (USP28) plays a role in the progression of various tumors and serves as a potential therapeutic target. This study aims to determine the role of USP28 in the progression of NSCLC. We examined the impact of the USP28 inhibitor AZ1 on the cell cycle, apoptosis, DNA damage response, and cellular immunogenicity in non-small cell lung cancer. We observed that AZ1 and siUSP28 induce DNA damage, leading to the activation of Noxa-mediated mitochondrial apoptosis. The dsDNA and mtDNA released from DNA damage and mitochondrial apoptosis activate tumor cell immunogenicity through the cGAS-STING signaling pathway. Simultaneously, targeting USP28 promotes the degradation of c-MYC, resulting in cell cycle arrest and inhibition of DNA repair. This further promotes DNA damage-induced cell apoptosis mediated by the Noxa protein, thereby enhancing tumor cell immunogenicity mediated by dsDNA and mtDNA. Moreover, we found that the combination of AZ1 and cisplatin (DDP) can enhance therapeutic efficacy, thereby providing a new strategy to overcome cisplatin resistance in NSCLC. These findings suggest that targeting USP28 and combining it with cisplatin are feasible strategies for treating NSCLC.
RESUMO
Objective: The purpose of this study was to investigate whether bacteriochlorophyll a (BCA) could be used as a potential diagnostic factor in near-infrared fluorescence (NIRF) imaging and in mediating sonodynamic antitumor effect. Methods: The UV spectrum and fluorescence spectra of bacteriochlorophyll a were measured. The IVIS Lumina imaging system was used to observe the fluorescence imaging of bacteriochlorophyll a. 9,10-Dimethylanthracene (DMA) reagent was used as a singlet oxygen sensor to detect singlet oxygen produced by bacteriochlorophyll a. LLC cells of mouse lung adenocarcinoma were selected as experimental subjects. Flow cytometry was used to detect the optimal uptake time of bacteriochlorophyll a in LLC cells. A laser confocal microscope was used to observe the binding of bacteriochlorophyll a to cells. The cell survival rate of each experimental group was detected by the CCK-8 method to detect the cytotoxicity of bacteriochlorophyll a. The effect of BCA-mediated sonodynamic therapy (SDT) on tumor cells was detected by the calcein acetoxymethyl ester/propidium iodide (CAM/PI) double staining method. 2,7-Dichlorodihydrofluorescein-diacetate (DCFH-DA) was used as the staining agent to evaluate and analyze intracellular reactive oxygen species (ROS) levels by fluorescence microscopy and flow cytometry (FCM). A confocal laser scanning microscope (CLSM) was used to observe the localization in the organelles of bacteriochlorophyll a. The IVIS Lumina imaging system was used to observe the fluorescence imaging of BCA in vitro. Results: Bacteriochlorophyll a-mediated SDT significantly increased cytotoxicity to LLC cells compared to other treatments, such as ultrasound (US) only, bacteriochlorophyll a only, and sham therapy. The CLSM observed bacteriochlorophyll a aggregation around the cell membrane and cytoplasm. FCM analysis and fluorescence microscopy showed that bacteriochlorophyll a-mediated SDT in LLC cells significantly inhibited cell growth and caused an obvious increase in intracellular ROS levels, and its fluorescence imaging function suggests that it can be a potential diagnostic factor. Conclusion: The results showed that bacteriochlorophyll a possesses good sonosensitivity and fluorescence imaging function. It can be effectively internalized in LLC cells, and bacteriochlorophyll a-mediated SDT is associated with ROS generation. This suggests that bacteriochlorophyll a can be used as a new type of sound sensitizer, and the bacteriochlorophyll a-mediated sonodynamic effect may be a potential treatment for lung cancer.
RESUMO
Oral mucositis (OM) caused by cancer therapy is the most common adverse reaction in the radiotherapy of head and neck tumors. In severe cases, it can lead to the interruption of treatment, which affects the control of the disease and the quality of life. Shuanghua Baihe Tablet (SBT) is a traditional Chinese medicine (TCM) formula, which is administerd to treat OM in China. It has been clinically effective for more than 30 years, but the underlying mechanism is not completely understood. With the development of multiple omics, it is possible to explore the mechanism of Chinese herbal compound prescriptions. Based on transcriptomics and metabolomics, we explored the underlying mechanism of SBT in the treatment of OM. An OM model of rats was established by 5-FU induction, and SBT was orally administered at dosages of 0.75 and 3 g·kg-1·d-1. In order to search for SBT targets and related metabolites, the dysregulated genes and metabolites were detected by transcriptomics and metabolomics. Immune related indicators such as interleukin-17 (IL-17) and tumor necrosis factor-α (TNF-α) were detected by ELISA. Treg cell disorders was analyzed by flow cytometry. Our results showed that SBT significantly alleviated the symptoms of OM rats and the inflammatory infiltration of ulcer tissues. After SBT administration, inflammatory related metabolic pathways including linoleic acid metabolism, valine, leucine and isoleucine biosynthesis were significantly altered. Furthermore, the production of proinflammatory factors like IL-17 and TNF-α, were also dramatically reduced after SBT administration. Besides, the infiltration degree of Treg cells in the spleen of OM modeling rats was significantly improved by SBT administration, thus maintaining the immune balance of the body. The current study demonstrates that SBT regulates inoleic acid metabolism, glycerophospholipid metabolism and amino acid metabolism, and inhibits IL-17/TNF signal transduction to restore Treg and Th17 cell homeostasis in OM rats, thereby alleviating chemotherapy-induced OM.
Assuntos
Medicamentos de Ervas Chinesas , Estomatite , Animais , Metaboloma , Qualidade de Vida , Ratos , Comprimidos , TranscriptomaRESUMO
O6-methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O6-position of guanine in DNA. MGMT expression is reduced or absent in many tumor types derived from a diverse range of tissues, most notably in glioma. Low MGMT expression confers significant sensitivity to DNA alkylating agents such as temozolomide, providing a natural therapeutic index over normal tissue. In this study, we sought to identify novel approaches that could maximally exploit the therapeutic index between tumor cells and normal tissues based on MGMT expression, as a means to enhance selective tumor cell killing. Temozolomide, unlike other alkylators, activated the ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (Chk1) axis in a manner that was highly dependent on MGMT status. Temozolomide induced growth delay, DNA double-strand breaks, and G2-M cell-cycle arrest, which led to ATR-dependent phosphorylation of Chk1; this effect was dependent on reduced MGMT expression. Treatment of MGMT-deficient cells with temozolomide increased sensitivity to ATR inhibitors both in vitro and in vivo across numerous tumor cell types. Taken together, this study reveals a novel approach for selectively targeting MGMT-deficient cells with ATR inhibitors and temozolomide. As ATR inhibitors are currently being tested in clinical trials, and temozolomide is a commonly used chemotherapeutic, this approach is clinically actionable. Furthermore, this interaction potently exploits a DNA-repair defect found in many cancers. SIGNIFICANCE: Monofunctional alkylating agents sensitize MGMT-deficient tumor cells to ATR inhibitors.
Assuntos
Antineoplásicos Alquilantes/farmacologia , Proteínas Mutadas de Ataxia Telangiectasia/antagonistas & inibidores , Metilases de Modificação do DNA/metabolismo , Enzimas Reparadoras do DNA/metabolismo , Isoxazóis/farmacologia , Pirazinas/farmacologia , Temozolomida/farmacologia , Proteínas Supressoras de Tumor/metabolismo , Animais , Antineoplásicos Alquilantes/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Proteínas Mutadas de Ataxia Telangiectasia/metabolismo , Pontos de Checagem do Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Quinase 1 do Ponto de Checagem/metabolismo , Quebras de DNA de Cadeia Dupla/efeitos dos fármacos , Dano ao DNA , Sinergismo Farmacológico , Feminino , Humanos , Isoxazóis/administração & dosagem , Camundongos Nus , Pirazinas/administração & dosagem , Temozolomida/administração & dosagem , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
Structure-based design led to the discovery of a novel class of renin inhibitors in which an unprecedented phenyl ring filling the S1 site is attached to the phenyl ring filling the S3 pocket. Optimization for several parameters including potency in the presence of human plasma, selectivity against CYP3A4 inhibition and improved rat oral bioavailability led to the identification of 8d which demonstrated antihypertensive efficacy in a transgenic rat model of human hypertension.
Assuntos
Anti-Hipertensivos/farmacologia , Inibidores Enzimáticos/farmacologia , Éteres Fenílicos/farmacologia , Renina/antagonistas & inibidores , Animais , Anti-Hipertensivos/síntese química , Anti-Hipertensivos/química , Disponibilidade Biológica , Cristalografia por Raios X , Citocromo P-450 CYP3A/sangue , Inibidores do Citocromo P-450 CYP3A , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Descoberta de Drogas , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/química , Humanos , Hipertensão/tratamento farmacológico , Modelos Moleculares , Conformação Molecular , Éteres Fenílicos/síntese química , Éteres Fenílicos/química , Ratos , Ratos Transgênicos , Proteínas Recombinantes/antagonistas & inibidores , Proteínas Recombinantes/isolamento & purificação , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.
RESUMO
Structure-guided drug design led to new alkylamine renin inhibitors with improved in vitro and in vivo potency. Lead compound 21a, has an IC(50) of 0.83nM for the inhibition of human renin in plasma (PRA). Oral administration of 21a at 10mg/kg resulted in >20h reduction of blood pressure in a double transgenic rat model of hypertension.